Symbicort Single Inhaler Therapy vs Conventional Best Practice for the Treatment of Persistent Asthma in Adults

Launched by ASTRAZENECA · Oct 6, 2006

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Minimum of 3 months history of asthma, diagnosed according to the American Thoracic Society (ATS) definition (9).
• • Prescribed inhaled GCS at a dose of 400μg/day of budesonide (or equivalents)and within the approved label for the relevant drug during the last 3 months prior to Visit 1.
• • Either daily maintenance treatment with both inhaled GCS and LABA or daily treatment with inhaled GCS alone (i.e. without LABA)
• • A history of suboptimal asthma control the month prior to enrolment as judged by the investigator
• • Use of ≥3 inhalations of as needed medication for symptom relief during the last 7 days before enrolment
• Exclusion Criteria:
• • Previous treatment with Symbicort Single Inhaler;
• • Use of any b-blocking agent, including eye-drops and oral GCS as maintenance treatment.
• • Known or suspected hypersensitivity to study therapy or excipients.
• • A history of smoking ≥ 10 pack years.
• • Asthma exacerbation requiring change in asthma treatment during the last 14 days prior to or at Visit 1.